Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 351

1.

Glycosylation facilitates transdermal transport of macromolecules.

Pino CJ, Gutterman JU, Vonwil D, Mitragotri S, Shastri VP.

Proc Natl Acad Sci U S A. 2012 Dec 26;109(52):21283-8. doi: 10.1073/pnas.1200942109. Epub 2012 Dec 10.

2.

The anticancer plant triterpenoid, avicin D, regulates glucocorticoid receptor signaling: implications for cellular metabolism.

Haridas V, Xu ZX, Kitchen D, Jiang A, Michels P, Gutterman JU.

PLoS One. 2011;6(11):e28037. doi: 10.1371/journal.pone.0028037. Epub 2011 Nov 21.

3.

Natural triterpenoid avicins selectively induce tumor cell death.

Wang H, Haridas V, Gutterman JU, Xu ZX.

Commun Integr Biol. 2010 May;3(3):205-8.

4.

Red blood cell permeabilization by hypotonic treatments, saponin, and anticancer avicins.

Arias M, Quijano JC, Haridas V, Gutterman JU, Lemeshko VV.

Biochim Biophys Acta. 2010 Jun;1798(6):1189-96. doi: 10.1016/j.bbamem.2010.03.018. Epub 2010 Mar 24.

5.

Avicin D, a plant triterpenoid, induces cell apoptosis by recruitment of Fas and downstream signaling molecules into lipid rafts.

Xu ZX, Ding T, Haridas V, Connolly F, Gutterman JU.

PLoS One. 2009 Dec 31;4(12):e8532. doi: 10.1371/journal.pone.0008532.

6.

Avicin D: a protein reactive plant isoprenoid dephosphorylates Stat 3 by regulating both kinase and phosphatase activities.

Haridas V, Nishimura G, Xu ZX, Connolly F, Hanausek M, Walaszek Z, Zoltaszek R, Gutterman JU.

PLoS One. 2009;4(5):e5578. doi: 10.1371/journal.pone.0005578. Epub 2009 May 18.

7.

Three catalytic lives linked by the Lasker Awards.

Gutterman JU, Hunt N.

Nat Med. 2008 Oct;14(10):1033-5. doi: 10.1038/nm1008-1033. No abstract available.

PMID:
18841143
8.

Avicin D selectively induces apoptosis and downregulates p-STAT-3, bcl-2, and survivin in cutaneous T-cell lymphoma cells.

Zhang C, Li B, Gaikwad AS, Haridas V, Xu Z, Gutterman JU, Duvic M.

J Invest Dermatol. 2008 Nov;128(11):2728-35. doi: 10.1038/jid.2008.138. Epub 2008 May 22.

9.

A plant triterpenoid, avicin D, induces autophagy by activation of AMP-activated protein kinase.

Xu ZX, Liang J, Haridas V, Gaikwad A, Connolly FP, Mills GB, Gutterman JU.

Cell Death Differ. 2007 Nov;14(11):1948-57. Epub 2007 Aug 10.

10.

Avicins, a novel plant-derived metabolite lowers energy metabolism in tumor cells by targeting the outer mitochondrial membrane.

Haridas V, Li X, Mizumachi T, Higuchi M, Lemeshko VV, Colombini M, Gutterman JU.

Mitochondrion. 2007 May;7(3):234-40. Epub 2007 Jan 12.

PMID:
17317337
11.

The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis.

Liang J, Shao SH, Xu ZX, Hennessy B, Ding Z, Larrea M, Kondo S, Dumont DJ, Gutterman JU, Walker CL, Slingerland JM, Mills GB.

Nat Cell Biol. 2007 Feb;9(2):218-24. Epub 2007 Jan 21.

PMID:
17237771
12.

Avicins, natural anticancer saponins, permeabilize mitochondrial membranes.

Lemeshko VV, Haridas V, Quijano Pérez JC, Gutterman JU.

Arch Biochem Biophys. 2006 Oct 15;454(2):114-22. Epub 2006 Aug 23.

PMID:
16962987
13.

Effects of the tumor inhibitory triterpenoid avicin G on cell integrity, cytokinesis, and protein ubiquitination in fission yeast.

Gutterman JU, Lai HT, Yang P, Haridas V, Gaikwad A, Marcus S.

Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12771-6. Epub 2005 Aug 23.

14.

Avicinylation (thioesterification): a protein modification that can regulate the response to oxidative and nitrosative stress.

Haridas V, Kim SO, Nishimura G, Hausladen A, Stamler JS, Gutterman JU.

Proc Natl Acad Sci U S A. 2005 Jul 19;102(29):10088-93.

15.

Mitochondria as integrators of information in an early-evolving animal: insights from a triterpenoid metabolite.

Blackstone NW, Kelly MM, Haridas V, Gutterman JU.

Proc Biol Sci. 2005 Mar 7;272(1562):527-31.

16.

Proapoptotic triterpene electrophiles (avicins) form channels in membranes: cholesterol dependence.

Li XX, Davis B, Haridas V, Gutterman JU, Colombini M.

Biophys J. 2005 Apr;88(4):2577-84. Epub 2005 Jan 14.

17.

Triterpenoid electrophiles (avicins) activate the innate stress response by redox regulation of a gene battery.

Haridas V, Hanausek M, Nishimura G, Soehnge H, Gaikwad A, Narog M, Spears E, Zoltaszek R, Walaszek Z, Gutterman JU.

J Clin Invest. 2004 Jan;113(1):65-73.

18.

Isolation and structures of avicins D and G: in vitro tumor-inhibitory saponins derived from Acacia victoriae.

Jayatilake GS, Freeberg DR, Liu Z, Richheimer SL, Blake Nieto ME, Bailey DT, Haridas V, Gutterman JU.

J Nat Prod. 2003 Jun;66(6):779-83.

PMID:
12828461
19.

Metabolomics of plant saponins: bioprospecting triterpene glycoside diversity with respect to mammalian cell targets.

Joshi L, Van Eck JM, Mayo K, Di Silvestro R, Blake Nieto ME, Ganapathi T, Haridas V, Gutterman JU, Arntzen CJ.

OMICS. 2002;6(3):235-46.

PMID:
12427275
21.

Avicins, a family of triterpenoid saponins from Acacia victoriae (Bentham), suppress H-ras mutations and aneuploidy in a murine skin carcinogenesis model.

Hanausek M, Ganesh P, Walaszek Z, Arntzen CJ, Slaga TJ, Gutterman JU.

Proc Natl Acad Sci U S A. 2001 Sep 25;98(20):11551-6.

22.

Triterpenoid saponins from Acacia victoriae (Bentham) decrease tumor cell proliferation and induce apoptosis.

Mujoo K, Haridas V, Hoffmann JJ, Wächter GA, Hutter LK, Lu Y, Blake ME, Jayatilake GS, Bailey D, Mills GB, Gutterman JU.

Cancer Res. 2001 Jul 15;61(14):5486-90.

23.

Phase I trial of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer.

Logothetis CJ, Wu KK, Finn LD, Daliani D, Figg W, Ghaddar H, Gutterman JU.

Clin Cancer Res. 2001 May;7(5):1198-203.

24.

Avicins: triterpenoid saponins from Acacia victoriae (Bentham) induce apoptosis by mitochondrial perturbation.

Haridas V, Higuchi M, Jayatilake GS, Bailey D, Mujoo K, Blake ME, Arntzen CJ, Gutterman JU.

Proc Natl Acad Sci U S A. 2001 May 8;98(10):5821-6.

25.
26.

Reduced growth rate and transformation phenotype of the prostate cancer cells by an interferon-inducible protein, p202.

Yan DH, Wen Y, Spohn B, Choubey D, Gutterman JU, Hung MC.

Oncogene. 1999 Jan 21;18(3):807-11.

27.

p202 self-associates through a sequence conserved among the members of the 200-family proteins.

Koul D, Obeyesekere NU, Gutterman JU, Mills GB, Choubey D.

FEBS Lett. 1998 Oct 30;438(1-2):21-4.

28.

A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix.

Kudelka AP, Levy T, Verschraegen CF, Edwards CL, Piamsomboon S, Termrungruanglert W, Freedman RS, Kaplan AL, Kieback DG, Meyers CA, Jaeckle KA, Loyer E, Steger M, Mante R, Mavligit G, Killian A, Tang RA, Gutterman JU, Kavanagh JJ.

Clin Cancer Res. 1997 Sep;3(9):1501-5.

29.

Recreating an environment for clinical discovery.

Gutterman JU.

Clin Cancer Res. 1997 Dec;3(12 Pt 2):2594-7. No abstract available.

30.

p202 prevents apoptosis in murine AKR-2B fibroblasts.

Koul D, Lapushin R, Xu HJ, Mills GB, Gutterman JU, Choubey D.

Biochem Biophys Res Commun. 1998 Jun 18;247(2):379-82.

PMID:
9642135
31.

Inhibition of E2F-4/DP-1-stimulated transcription by p202.

Choubey D, Gutterman JU.

Oncogene. 1997 Jul 17;15(3):291-301.

32.

Clinical investigators: the driving force behind drug discovery.

Gutterman JU.

Nat Biotechnol. 1997 Jul;15(7):598-9. Review. No abstract available.

PMID:
9219248
33.

Inhibition of E2F-mediated transcription by p202.

Choubey D, Li SJ, Datta B, Gutterman JU, Lengyel P.

EMBO J. 1996 Oct 15;15(20):5668-78.

34.

Interferon-alpha-induced human lupus inclusions and p36 protein in cancer and AIDS.

Vakharia DD, Szebenyi SE, Gutterman JU, Rich SA.

J Interferon Cytokine Res. 1996 Sep;16(9):709-15.

PMID:
8887055
35.

Adenoviral-mediated p53 tumor suppressor gene therapy of human ovarian carcinoma.

Mujoo K, Maneval DC, Anderson SC, Gutterman JU.

Oncogene. 1996 Apr 18;12(8):1617-23.

PMID:
8622881
36.

The interferon-inducible growth-inhibitory p202 protein: DNA binding properties and identification of a DNA binding domain.

Choubey D, Gutterman JU.

Biochem Biophys Res Commun. 1996 Apr 16;221(2):396-401.

PMID:
8619867
37.

The Lasker Awards at fifty.

DeBakey ME, Gutterman JU.

JAMA. 1995 Oct 4;274(13):1061. No abstract available.

PMID:
7563459
38.

Recombinant human retinoblastoma protein inhibits cancer cell growth.

Pagliaro LC, Antelman D, Johnson DE, Machemer T, McCulloch EA, Freireich EJ, Stass SA, Shepard HM, Maneval D, Gutterman JU.

Cell Growth Differ. 1995 Jun;6(6):673-80.

39.

Cytokine therapeutics: lessons from interferon alpha.

Gutterman JU.

Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1198-205. Review.

40.

Granulocyte-macrophage colony-stimulating factor as a cause of paraneoplastic leukaemoid reaction in advanced transitional cell carcinoma.

Wetzler M, Estrov Z, Talpaz M, Markowitz A, Gutterman JU, Kurzrock R.

J Intern Med. 1993 Oct;234(4):417-20.

PMID:
7691980
41.

A phase-I clinical study of low-dose oral interferon-alpha.

Dhingra K, Duvic M, Hymes S, McLaughlin P, Rothberg J, Gutterman JU.

J Immunother Emphasis Tumor Immunol. 1993 Jul;14(1):51-5.

PMID:
8399070
42.

Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer.

Danhauser LL, Freimann JH Jr, Gilchrist TL, Gutterman JU, Hunter CY, Yeomans AC, Markowitz AB.

J Clin Oncol. 1993 Apr;11(4):751-61.

PMID:
8478667
43.
44.

CHOP-Bleo plus interferon for stage IV low-grade lymphoma.

McLaughlin P, Cabanillas F, Hagemeister FB, Swan F Jr, Romaguera JE, Taylor S, Rodriguez MA, Velasquez WS, Redman JR, Gutterman JU.

Ann Oncol. 1993 Mar;4(3):205-11.

PMID:
7682436
45.

Suppression of chronic myelogenous leukemia colony growth by interleukin-4.

Estrov Z, Markowitz AB, Kurzrock R, Wetzler M, Kantarjian HM, Ferrajoli A, Gutterman JU, Talpaz M.

Leukemia. 1993 Feb;7(2):214-20.

PMID:
8426475
46.

Intensive preoperative chemotherapy with colony-stimulating factor for resectable adenocarcinoma of the esophagus or gastroesophageal junction.

Ajani JA, Roth JA, Ryan MB, Putnam JB, Pazdur R, Levin B, Gutterman JU, McMurtrey M.

J Clin Oncol. 1993 Jan;11(1):22-8.

PMID:
8418237
47.

Ubiquitous expression of cytokines in diverse leukemias of lymphoid and myeloid lineage.

Kurzrock R, Kantarjian H, Wetzler M, Estrov Z, Estey E, Troutman-Worden K, Gutterman JU, Talpaz M.

Exp Hematol. 1993 Jan;21(1):80-5.

PMID:
8417962
48.

Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer.

Buzdar AU, Hortobagyi GN, Kau SW, Smith TL, Fraschini G, Holmes FA, Gutterman JU, Hug VM, Singletary SE, Ames FC, et al.

J Clin Oncol. 1992 Oct;10(10):1540-6.

PMID:
1403033
49.

Biologic therapy of human cancer.

Gutterman JU.

Cancer. 1992 Aug 15;70(4 Suppl):906-8. No abstract available.

PMID:
1638462
50.

Minimal residual disease in interferon-treated chronic myelogenous leukemia: results and pitfalls of analysis based on polymerase chain reaction.

Dhingra K, Kurzrock R, Kantarjian H, Baine R, Eastman PS, Ku S, Gutterman JU, Talpaz M.

Leukemia. 1992 Aug;6(8):754-60.

PMID:
1640725

Supplemental Content

Loading ...
Support Center